IMMUNIC, INC.

NEW YORK, X1 · Biotech · Public

Selective oral immunology therapeutics for chronic inflammatory and autoimmune diseases

Claim this profile

Follows are private to you and power your alerts

Updated · imux.com

Sector
Biotech
Headquarters
NEW YORK, X1
Latest Form D
$200M, Mar 2026
Total capital
$470M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$470M
10 Form D · last Mar 2026
8 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20092013201720212025FEDERAL ↑EQUITY ↓Cumulative $470M8th Form D$60M
20092013201720212025FEDERAL ↑EQUITY ↓Cumulative $470M

Latest events

  • Private capital raisedForm D · SEC · 10th filing$200M
  • Private capital raisedForm D · SEC · 9th filing$80M
  • Private capital raisedForm D · SEC · 8th filing$60M
  • Private capital raisedForm D · SEC · 7th filing$12M
  • Private capital raisedForm D · SEC · 6th filing$14.3M
  • Private capital raisedForm D · SEC · 5th filing$76.1M
  • Private capital raisedForm D · SEC · 4th filing$2.5M
  • Private capital raisedForm D · SEC · 3rd filing$930K
  • Private capital raisedForm D · SEC · 2nd filing$22.6M
  • Private capital raisedForm D · SEC · 1st filing$1.2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Andreas MuehlerExecutive OfficerNamed in SEC Form D filings
  • Barclay PhillipsDirectorNamed in SEC Form D filings
  • DANIEL VITTExecutive Officer, DirectorNamed in SEC Form D filings
  • DUANE NASHDirectorNamed in SEC Form D filings
  • Glenn WhaleyExecutive OfficerNamed in SEC Form D filings
  • Hella KohlhofExecutive OfficerNamed in SEC Form D filings
Show all 19 people
  • Inderpal SinghExecutive OfficerNamed in SEC Form D filings
  • JASON TARDIOExecutive OfficerNamed in SEC Form D filings
  • JOERG NEERMANDirectorNamed in SEC Form D filings
  • Jorg NeermanDirectorNamed in SEC Form D filings
  • Jorg NeermannDirectorNamed in SEC Form D filings
  • Maria TornsenDirectorNamed in SEC Form D filings
  • Monika Maria TornsenDirectorNamed in SEC Form D filings
  • Patrick WalshExecutive OfficerNamed in SEC Form D filings
  • RICHARD RUDICKDirectorNamed in SEC Form D filings
  • SIMONA SKERJANECDirectorNamed in SEC Form D filings
  • Tamar HowsonDirectorNamed in SEC Form D filings
  • THORVALD NAGELDirectorNamed in SEC Form D filings
  • Vincent OssipowDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .